Zambon Central Nervous System

Central Nervous System

We continue to invest in research aimed at improving the quality of life of patients suffering from Parkinson's disease and ALS.

Parkinson's Disease: the second most common neurodegenerative disease worldwide

Parkinson's is a progressive disease that mainly affects certain functions, such as the control of movements and balance. Due to the aging of the population and diseases connected with this phenomenon, a global increase in the number of people suffering from Parkinson's disease is expected.  

* Source: www.parkinson.it/morbo-di-parkinson.html

6 Mil

The number of people suffering from Parkinson's disease worldwide

Source: The Global Burden of Disease Study, 2016
60 years

The average age worldwide for the onset of Parkinson's

Source: GBI Research, 2013
10%

The percentage worldwide of people suffering from the disease who are less than 40 years old

Source: GBI Research, 2013
Parkinson_sistema nervoso

We continue to invest in improving the quality of life of patients suffering from Parkinson's Disease

We started investing in the Central Nervous System in 2015, focusing our efforts on research into Parkinson’s disease, a treatment sector in which there had been no new developments for years. 

Since 2015, 60,000 patients have been able to benefit from these investments by means of an innovative molecule that constitutes a decisive step forward in the treatment of this chronic disease.

It is important to continue offering new solutions in this sector, and this is why at Zambon we study patient-focused products and solutions, and value partnerships as well as ad hoc industrial, research or marketing projects.

Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder with a prevalence of  5-7 cases per 100.000. It is characterized by progressive muscular paralysis reflecting degeneration of motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. There is NO cure for ALS,  therapy consists in symptomatic drug treatment, medications to slow the progression, exercise, adjustments in the home and ALS-team (neurologist, physiotherapist, nurse).

58-60 years

average age of onset of ALS

1 - 2.6

cases per 100000 persons annually

Zambon is committed to improve people’s quality of life

Thanks to the collaboration with Aquestive, Zambon further strengthened its commitment to orphan diseases and to the CNS area, enriching its portfolio with a new formulation that will concretely help ALS patients. Zambon is committed to improve people’s quality of life through innovative medicines and modern therapeutic solutions where they are mostly needed.

Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Phase 3
Safinamide for levodopa-induced dyskinesia
Phase 4
Safinamide for Pain in PD patients
Phase 2
Safinamide for MSA
Phase 3
ALS
contact
PARTNERNING OPPORTUNITIES
Business Development Department
+39 02 66524455